Clinical Trials · NCT04557059
A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
- Phase
- Phase 3
- Recruitment status
- Active Not Recruiting
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
- Enrollment
- 692
- Start date
- Nov 2020
- Locations
- 141 sites, 21 countries
- Primary endpoint
- Prostate specific Membrane Antigen-Positron Emission Tomography (PSMA-PET) Metastatic Progression-free Survival (ppMPFS)